Maravai LifeSciences HoldingsMRVI -1.44%62 PB Ratio is 4.29 as of Jul. 01, 2026, which is 35% above its 10-year median of 3.18. GuruFocus rates MRVI with a GF Score™ of 62/100 and a GF Value™ of $3.82 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,229 Biotechnology companies, Maravai LifeSciences Holdings ranks worse than 65.34% on this metric.
Maravai LifeSciences Holdings Inc stock PB Ratio (=4.35) is close to 3-year high of 4.35.
The historical rank and industry rank for Maravai LifeSciences Holdings's PB Ratio or its related term are showing as below:
MRVI'
s PB Ratio Range Over the Past 10 Years
Min: 0.85 Med: 3.18 Max: 39.36
Current: 4.3
During the past 8 years, Maravai LifeSciences Holdings's highest PB Ratio was 39.36. The lowest was 0.85. And the median was 3.18.
MRVI's PB Ratio is ranked worse than 65.34% of 1229
companies
in the Biotechnology industry
Industry Median: 2.87
vs MRVI: 4.30
During the past 12 months, Maravai LifeSciences Holdings's average Book Value Per Share Growth Rate was -31.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -29.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 5.70% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Maravai LifeSciences Holdings was 51.00% per year. The lowest was -29.30% per year. And the median was 13.90% per year.
Back to Basics: PB Ratio
Maravai LifeSciences Holdings (NAS:MRVI) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Maravai LifeSciences Holdings PB Ratio Related Terms
Maravai LifeSciences Holdings PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Maravai LifeSciences Holdings's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maravai LifeSciences Holdings PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's PB Ratio distribution charts can be found below:
* The bar in red indicates where Maravai LifeSciences Holdings's PB Ratio falls into.
Maravai LifeSciences Holdings PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Maravai LifeSciences Holdings (MRVI) has a PB Ratio of 4.29 as of Jul. 01, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Maravai LifeSciences Holdings and its competitors. This is 35% above median its historical median of 3.18. Over the past decade, Maravai LifeSciences Holdings' PB Ratio has ranged from 0.85 to 39.36. According to the industry distribution chart, Maravai LifeSciences Holdings ranks #803 out of 1229 companies in the Biotechnology industry, placing it in the top 65.3%.
Is Maravai LifeSciences Holdings' PB Ratio too high?
Maravai LifeSciences Holdings' current PB Ratio of 4.29 is 35% above median its 10-year median of 3.18. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 39.36. The Biotechnology industry median PB Ratio is 2.87. Maravai LifeSciences Holdings' value of 4.29 is 49.5% above this industry median. Based on the distribution chart, Maravai LifeSciences Holdings ranks #803 out of 1229 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Maravai LifeSciences Holdings has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' PB Ratio compare to LBRX and SLDB?
According to the Biotechnology industry distribution chart, Maravai LifeSciences Holdings ranks #803 out of 1229 companies for PB Ratio. This places Maravai LifeSciences Holdings in the lower half of its industry. The industry median PB Ratio is 2.87. Maravai LifeSciences Holdings' value of 4.29 is 49.5% above this benchmark. Historically, Maravai LifeSciences Holdings' own PB Ratio has ranged from 0.85 to 39.36 over the past decade. While the company's 10-year median is 3.18 vs. the industry median of 2.87, Maravai LifeSciences Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.87, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maravai LifeSciences Holdings's current PB Ratio of 4.29 is 49.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Maravai LifeSciences Holdings and its competitors. For the Biotechnology industry, the median PB Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maravai LifeSciences Holdings's current PB Ratio is 4.29, which is 35% above median its own 10-year median of 3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings (MRVI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.82, compared to a current price of $6.15 — trading 61% above its estimated fair value. The current PB Ratio is 4.29, which is 35% above median its 10-year median of 3.18 and 49.5% above the Biotechnology industry median of 2.87. Maravai LifeSciences Holdings' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MRVI), the current PB Ratio is 4.29 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of $6.15 is trading 61% above its estimated GF Value™ of $3.82.
GuruFocus considers Maravai LifeSciences Holdings to be Significantly Overvalued.
Key valuation signals for MRVI:
PB Ratio: 4.29 (35% above median its 10-year median of 3.18)
GF Value™: $3.82 vs. price of $6.15 (61% above fair value)
Industry Position: 49.5% above the Biotechnology median (#803 of 1229)
No single metric tells the full story. See the MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Business Description
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score
Get the complete analysis for MRVI
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MRVI has been successfully added to your 
